The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Prognostic factors and clinical outcomes in patients with leptomeningeal metastasis from solid tumors.
Abstract
Background Leptomeningeal metastasis (LM) occurs in 4-15% of patients with solid tumors. Although the clinical outcomes in cancer patients have been improving recently, no standard treatment for LM has been established as yet. The purpose of this study was to identify the prognostic factors in patients with solid tumors with cytologically proven LM.Methods We retrospectively analyzed a series of 85 consecutive patients with cytologically proven LM who were treated between 1997 and 2005.Results The primary diseases were as follows; lung cancer (n = 36), breast cancer (n = 33), gastric cancer (n = 8), and others (n = 8). Forty-nine patients had brain metastasis at the time of diagnosis of the LM, and in 51 patients, MRI revealed meningeal dissemination in the brain or spine. The performance status (PS) was 0-1 in 26 patients and 2-4 in 59 patients. Thirty-one patients, including 19 with breast cancer, four with lung cancer, five with gastric cancer and three with other cancers, were treated by intrathecal (IT) chemotherapy. The response rate to the IT was 52% (95% confidence interval (CI): 41.4-62.6%). The median survival was 51 days (range, 3-759 days). A univariate analysis identified breast cancer, good PS (0-1), time to development of the LM (>1 year), and treatment by IT chemotherapy as being associated with a good prognosis, and multivariate analysis identified poor PS (HR: 1.72 (95% CI, 1.04-2.86) P = 0.04) and MRI-proven LM (HR: 1.82 (95% CI, 1.11-2.98) P = 0.02) as being associated with a poor prognosis.Conclusion In patients with poor prognostic factors, such as poor PS or MRI-proven LM, palliative therapy might be the most suitable treatment strategy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Primary tumors of the meninges are quite rare, however, the leptomeninges is a relatively common site for by contiguous extension of primary tumors of the central nervous system, paranasal sinuses and skull base origin or tumor metastasis which can lead to dissemination into the CNS parenchyma and poor prognosis”
From Living on the Edge of the CNS: Meninges Cell Diversity in Health and Disease (2021) · cites this paper as Waki et al., 2009
Citations
Cites
Clemente, C. G., Mihm, M. C., Bufalino, R., Zurrida, S., Collini, P., & Cascinelli, N. (1996) · Cancer · doi:10.1002/(sici)1097-0142(19960401)77:7 · Cited by 1,194
Intraductal carcinoma of the breast: Follow-up after biopsy only
Page, D. L., Dupont, W. D., Rogers, L. W., & Landenberger, M. (1982) · Cancer · doi:10.1002/1097-0142(19820215)49:4 · Cited by 600
Grossman, S. A., & Krabak, M. J. (1999) · Cancer Treatment Reviews · doi:10.1053/ctrv.1999.0119 · Cited by 534
Malignant cells in cerebrospinal fluid (CSF)
Glass, J. P., Melamed, M. R., Chernik, N. L., & Posner, J. B. (1979) · Neurology · doi:10.1212/wnl.29.10.1369 · Cited by 494
Neuroimaging and cerebrospinal fluid cytology in the diagnosis of leptomeningeal metastasis
Freilich, R. J., Krol, G. S., & DeAngelis, L. M. (1995) · Annals of Neurology · doi:10.1002/ana.410380111 · Cited by 417
Grossman, S. A., Finkelstein, D. M., Ruckdeschel, J. C., Trump, D. L., Moynihan, T. J., & Ettinger, D. S. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.3.561 · Cited by 364
Neurologic Complications of Cancer
Wen, P. Y., & Glantz, M. (2003) · Neurologic Clinics · doi:10.1016/s0733-8619(02)00100-7 · Cited by 362
HITCHINS, R. N., Bell, D. R., Woods, R., & Levi, J. A. (1987) · Journal of Clinical Oncology · doi:10.1200/jco.1987.5.10.1655 · Cited by 352
Boogerd, W. J., van den Bent, M. J., Koehler, P. J., Heimans, J. J., van der Sande, J. J., Aaronson, N. K., Hart, A. A. M., Benraadt, J., & Vecht, C. J. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2004.08.012 · Cited by 287
Suki, D., AbouAssi, H., Patel, A. J., Sawaya, R. A., Weinberg, J. S., & Groves, M. D. (2008) · Journal of neurosurgery · doi:10.3171/jns/2008/108/2/0248 · Cited by 179
Research works printed but not linked: 1
- NCCN Clinical Practice Guideline in Oncology (2007) Central nervous system cancers, carcinomatous/lymphomatous meningitis (CLMEN-1). Version 1:21–24
Cited by
Sorted by citations
Leptomeningeal metastases in the MRI era
Clarke, J. L., Perez, H. R., Jacks, L. M., Panageas, K. S., & DeAngelis, L. M. (2010) · Neurology · doi:10.1212/wnl.0b013e3181dc1a69 · Cited by 431
Complement Component 3 adapts the cerebrospinal fluid for leptomeningeal metastasis.
Boire, A., Zou, Y., Shieh, J., Macalinao, D. G., Pentsova, E., & Massagué, J. (2017) · Cell · doi:10.1016/j.cell.2017.02.025 · Cited by 366
Carcinomatous meningitis: Leptomeningeal metastases in solid tumors
Chamberlain, M. C., Rhun, É. L., & Taillibert, S. (2013) · Surgical Neurology International · doi:10.4103/2152-7806.111304 · Cited by 342
Leptomeningeal metastasis from systemic cancer: Review and update on management
Wang, N., Bertalan, M. S., & Brastianos, P. K. (2017) · Cancer · doi:10.1002/cncr.30911 · Cited by 262
Chamberlain, M. C. (2010) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32833de986 · Cited by 193
Metadata
- Authors
- Waki, F., Ando, M., Takashima, A., Yonemori, K., Nokihara, H., Miyake, M., Tateishi, U., Tsuta, K., Shimada, Y., Fujiwara, Y., & Tamura, T.
- Affiliations
- National Cancer Center Hospital (JP)
- Corresponding author
- Waki, Fusako
- ORCID
- Venue
- Journal of Neuro-Oncology
- Published
- 2008-11-29
- Volume
- 93
- Issue
- 2
- Pages
- 205-212
- ISSN
- 0167-594X (ISSN-L)
- 1573-7373
- OpenAlex
- W2152333631
- Cited by
- 145
- References
- 25
- Citations by year
- 2026: 2 · 2025: 9 · 2024: 7 · 2023: 6 · 2022: 9 · 2021: 10 · 2020: 15 · 2019: 14 · 2018: 11 · 2017: 6 · 2016: 11 · 2015: 6 · 2014: 3 · 2013: 11 · 2012: 8
- FWCI
- 5.22
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Journal of Neuro-Oncology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Brain Metastases and Treatment
- Health Sciences › Medicine › Surgery › Management of metastatic bone disease
- Health Sciences › Medicine › Oncology › Cancer survivorship and care
- Keywords
- leptomeningeal metastasis, solid tumors, prognostic factors, intrathecal chemotherapy, performance status, breast cancer, lung cancer, gastric cancer, brain metastases, survival, palliative care
- MeSH terms
- Adult, Aged, Aged, 80 and over, Brain Neoplasms, Breast Neoplasms, Female, Humans, Lung Neoplasms, Male, Meningeal Neoplasms, Middle Aged, Neoplasm Metastasis, Neoplasms, Prognosis, Retrospective Studies, Spinal Cord Neoplasms, Stomach Neoplasms, Time Factors, Survival Analysis, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
